

Table 1. Patient demographics and clinical characteristics

| Variable                           | No Event (N=207) | Event (N=23) | p-value |
|------------------------------------|------------------|--------------|---------|
| <b>Age mean (sd)</b>               | 35.4 (4.16)      | 33.7 (5.39)  | 0.141   |
| <b>BMI (sd)</b>                    | 21.9 (3.29)      | 21.4 (2.68)  | 0.462   |
| <b>Comorbidity (%)</b>             |                  |              | 1.000   |
| No                                 | 187 (90.3)       | 21 (91.3)    |         |
| Yes                                | 20 (9.7)         | 2 (8.7)      |         |
| <b>Histology grade (%)</b>         |                  |              | 0.181   |
| 1                                  | 79 (40.5)        | 6 (30)       |         |
| 2                                  | 88 (45.1)        | 8 (40)       |         |
| 3                                  | 28 (14.4)        | 6 (30)       |         |
| <b>Histology type (%)</b>          |                  |              | 0.584   |
| IDC                                | 179 (86.5)       | 21 (91.3)    |         |
| ILC                                | 6 (2.9)          | 1 (4.3)      |         |
| Mucinous carcinoma                 | 21 (10.1)        | 1 (4.3)      |         |
| Others                             | 1 (0.5)          | 0            |         |
| <b>Laterality (%)</b>              |                  |              | 0.826   |
| Left                               | 104 (50.2)       | 11 (47.8)    |         |
| Right                              | 103 (49.8)       | 12 (52.2)    |         |
| <b>LVSI (%)</b>                    |                  |              | 0.191   |
| Absence                            | 142 (75.1)       | 13 (61.9)    |         |
| Presence                           | 47 (24.9)        | 8 (38.1)     |         |
| <b>PNI (%)</b>                     |                  |              | 0.138   |
| Absence                            | 167 (87.9)       | 21 (100)     |         |
| Presence                           | 23 (12.1)        | 0            |         |
| <b>Focality (%)</b>                |                  |              | 0.074   |
| Unifocal                           | 188 (90.8)       | 18 (78.3)    |         |
| Multifocal                         | 19 (9.2%)        | 5 (21.7)     |         |
| <b>ER% (sd)</b>                    | 86.1 (18.48)     | 83.0 (18.63) | 0.447   |
| <b>PR% (sd)</b>                    | 65.6 (33.21)     | 46.9 (34.98) | 0.011   |
| <b>KI-67% (sd)</b>                 | 16.7 (13.3)      | 31.0 (21.1)  | 0.001   |
| <b>Tumor stage (%)</b>             |                  |              | 0.247   |
| T1                                 | 129 (62.3)       | 13 (56.5)    |         |
| T2                                 | 73 (35.3)        | 8 (34.8)     |         |
| T3                                 | 5 (2.4)          | 2 (8.7)      |         |
| <b>Lymph node stage (%)</b>        |                  |              | 0.153   |
| N0                                 | 196 (94.7)       | 20 (87)      |         |
| N1mi                               | 11 (5.3)         | 3 (13)       |         |
| <b>Hormone therapy (%)</b>         |                  |              | 1.00    |
| No                                 | 1 (0.5)          | 0            |         |
| Yes                                | 205 (99.5)       | 22 (100)     |         |
| <b>Addition of GnRH or BSO (%)</b> |                  |              | 0.505   |
| No                                 | 125 (60.4)       | 12 (52.2)    |         |
| Yes                                | 82 (39.6)        | 11 (47.8)    |         |
| <b>Radiotherapy (%)</b>            |                  |              | 0.096   |
| No                                 | 61 (29.5)        | 11 (47.8)    |         |
| Yes                                | 146 (70.5)       | 12 (52.2)    |         |
| <b>Chemotherapy (%)</b>            |                  |              | 0.062   |
| No                                 | 123 (59.4)       | 9 (39.1)     |         |
| Yes                                | 84 (40.6)        | 14 (60.9)    |         |

IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, LVSI: lymphovascular stromal invasion, PNI: perineural invasion, ER: estrogen receptor; PR: progesterone receptor; GnRH: gonadotropin releasing hormone; BSO: bilateral salpingo-oophorectomy